small molecule

OMEPRAZOLE

OMEPRAZOLE

Loss of exclusivityDecember 2036latest FDA-listed patent expiry
CompanyDEXCEL PHARMA TECHNOLOGIES LTD

Drug detail

Brand nameOMEPRAZOLE
Active ingredientOMEPRAZOLE
Strength20MG
Dosage formTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2017
Marketing statusOTC

Listed patents

PatentExpiresType
10835488December 2036product
10076494December 2036product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OMEPRAZOLE patent cliff — loss of exclusivity December 2036 | CliffBio